Skip to main content

Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.

Krupa Sivamurthy

Executive Medical Director (Immunology), US Medical Affairs

Krupa Sivamurthy 1600x900

Krupa Sivamurthy has over 12 years of experience in medical affairs. She joined CSL Behring in 2020 as the Hematology Therapeutic Area Lead where she was responsible for products such as Idelvion, Afstyla, Kcentra, Fibrinogen and Albumin. She led the global medical launch of Hemgenix, the first gene therapy for Hemophilia B.   She joined the US Medical Affairs team in 2023 as Executive Medical Director of Immunology.

Prior to joining CSL Behring, Krupa held a variety of Medical Leadership roles with expertise in Rare Disease and Global Medical Affairs at Pfizer. She had led the establishment of Medical Affairs team for Sickle Cell Disease.

Krupa earned her Doctor of Medicine degree with a specialization in Pediatrics from MS Ramaiah Medical College, Bangalore, and completed a registrar-ship in Hematology from Christian Medical College, Vellore. After re-locating to Philadelphia, she completed a residency in Pediatrics from Albert Einstein Medical Center and a Fellowship in Pediatric Hematology-Oncology from St Christopher’s Hospital for Children, Philadelphia.

Return to Leadership Team

For U.S. Healthcare Professionals only
For U.S. Healthcare Professionals only

The purpose of this CSL Behring Medical Affairs website is to support Healthcare Professionals with scientific information. This website is also a channel for U.S. Healthcare Professionals to submit questions or connect with CSL Behring U.S. Healthcare Professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US Healthcare Professional

toggle chat overlay
toggle chat overlay